- Home
- CMPX vs CRDF Comparison
CMPX vs CRDF Comparison
Compare CMPX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- CRDF
- Stock Information
- Founded
- CMPX 2014
- CRDF 1999
- Country
- CMPX United States
- CRDF United States
- Employees
- CMPX N/A
- CRDF N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPX Health Care
- CRDF Health Care
- Exchange
- CMPX Nasdaq
- CRDF Nasdaq
- Market Cap
- CMPX 214.6M
- CRDF 240.2M
- IPO Year
- CMPX N/A
- CRDF N/A
- Fundamental
- Price
- CMPX $2.60
- CRDF $3.45
- Analyst Decision
- CMPX Strong Buy
- CRDF Strong Buy
- Analyst Count
- CMPX 4
- CRDF 3
- Target Price
- CMPX $13.75
- CRDF $10.33
- AVG Volume (30 Days)
- CMPX 2.2M
- CRDF 1.4M
- Earning Date
- CMPX 11-12-2024
- CRDF 02-27-2025
- Dividend Yield
- CMPX N/A
- CRDF N/A
- EPS Growth
- CMPX N/A
- CRDF N/A
- EPS
- CMPX N/A
- CRDF N/A
- Revenue
- CMPX $850,000.00
- CRDF $688,000.00
- Revenue This Year
- CMPX N/A
- CRDF $25.03
- Revenue Next Year
- CMPX $613.39
- CRDF N/A
- P/E Ratio
- CMPX N/A
- CRDF N/A
- Revenue Growth
- CMPX N/A
- CRDF 49.57
- 52 Week Low
- CMPX $0.77
- CRDF $1.44
- 52 Week High
- CMPX $2.70
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- CMPX 76.97
- CRDF 45.05
- Support Level
- CMPX $1.43
- CRDF $3.33
- Resistance Level
- CMPX $2.70
- CRDF $4.89
- Average True Range (ATR)
- CMPX 0.29
- CRDF 0.31
- MACD
- CMPX 0.12
- CRDF -0.15
- Stochastic Oscillator
- CMPX 92.31
- CRDF 10.56
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").